Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + midazolam + remifentanil
- Development stage
- Unknown
- Lead developer
- Orion Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of three sedative and analgesic agents used for procedural sedation and analgesia. Dexmedetomidine is a selective α-2 adrenoceptor agonist with sedative, analgesic, and anxiolytic properties that causes minimal respiratory depression. Midazolam is a benzodiazepine sedative. Remifentanil is an ultra-short acting opioid with a constant half-life and antitussive effects. This combination may be used in various procedures requiring conscious sedation.
02
Targets
ADRA2A (α2A)MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on dexmedetomidine + midazolam + remifentanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + midazolam + remifentanil.